Buspirone: What is it all about?

被引:152
作者
Loane, C. [1 ]
Politis, M. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Div Expt Med, Dept Med, London, England
关键词
Buspirone; 5-HT; Neurology; Psychiatry; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN-REUPTAKE INHIBITORS; LEVODOPA-INDUCED DYSKINESIAS; PARKINSONS-DISEASE; DOUBLE-BLIND; 5-HT1A AGONIST; MAJOR DEPRESSION; ADJUVANT BUSPIRONE; TARDIVE-DYSKINESIA; TREATED PATIENTS;
D O I
10.1016/j.brainres.2012.04.032
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Buspirone is an anxiolytic drug and is a partial agonist for the serotonin 5-HT1A receptors as well as possessing low affinity and is an antagonist for the dopamine D-2 autoreceptors, with some evidence of a weak affinity to 5-HT2 receptors. The underlying mechanism of action of buspirone is not clear, however it is thought that its main pharmacology is mediated via the 5-HT1A receptors. Initially developed for use in the treatment of generalised anxiety disorder, it appears that buspirone may be useful in various other neurological and psychiatric disorders, such as attenuating side effects of Parkinson's disease therapy, ataxia, depression, social phobia, and behaviour disturbances following brain injury, and those accompanying Alzheimer's disease, dementia and attention deficit disorder. Considering the potential of this drug to be included in the management of many conditions, thorough and controlled studies are required to elucidate the exact mechanism of action. This review will consider the evidence so far for both the potential underlying mechanisms and its use in various conditions. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:111 / 118
页数:8
相关论文
共 91 条
[1]  
Aghajanian G., 1974, FRONT NEUROL, P4
[2]   Duloxetine-Induced Nocturnal Bruxism Resolved by Buspirone: Case Report [J].
Albayrak, Yakup ;
Ekinci, Okan .
CLINICAL NEUROPHARMACOLOGY, 2011, 34 (04) :137-138
[3]   Buspirone: Future directions [J].
Apter, JT ;
Allen, LA .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (01) :86-93
[4]   The psychobiology of anxiolytic drugs - Part 2: pharmacological treatments of anxiety [J].
Argyropoulos, SV ;
Sandford, JJ ;
Nutt, DJ .
PHARMACOLOGY & THERAPEUTICS, 2000, 88 (03) :213-227
[5]   Treatment of spinocerebellar ataxia with buspirone [J].
Assadi, Mitra ;
Campellone, Joseph V. ;
Janson, Christopher G. ;
Veloski, J. Jon ;
Schwartzman, Robert J. ;
Leone, Paola .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2007, 260 (1-2) :143-146
[6]   Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease [J].
Bara-Jimenez, W ;
Bibbiani, F ;
Morris, MJ ;
Dimitrova, T ;
Sherzai, A ;
Mouradian, MM ;
Chase, TN .
MOVEMENT DISORDERS, 2005, 20 (08) :932-936
[7]   Brain imaging after neural transplantation [J].
Bjorklund, Anders ;
Cenci, M. Angela .
RECENT ADVANCES IN PARKINSONS DISEASE: TRANSLATIONAL AND CLINICAL RESEARCH, 2010, 184 :193-203
[8]  
BOHM C, 1990, J CLIN PSYCHIAT, V51, P309
[9]   BUSPIRONE IN LEVODOPA-INDUCED DYSKINESIAS [J].
BONIFATI, V ;
FABRIZIO, E ;
CIPRIANI, R ;
VANACORE, N ;
MECO, G .
CLINICAL NEUROPHARMACOLOGY, 1994, 17 (01) :73-82
[10]   Buspirone vs haloperidol - A double-blind trial for agitation in a nursing home population with Alzheimer's disease [J].
Cantillon, M ;
Brunswick, R ;
Molina, D ;
Bahro, M .
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 1996, 4 (03) :263-267